Flamel Technologies Announces Projected Release Date of Fourth Quarter 2012 Results and Conference Call
23 2월 2013 - 2:16AM
Marketwired
Flamel Technologies (NASDAQ: FLML) expects to release certain
financial results for the fourth quarter of 2012, on Thursday,
February 28, 2013, before the market open. A conference call to
discuss these results has been scheduled for Thursday, February
28th at 8:30 AM (Eastern Standard Time). A question and answer
period will follow management's prepared remarks.
To participate in the conference call, investors are invited to
dial 888-417-8533. The conference ID number is 6788004. The
conference call webcast may be accessed at www.flamel.com.
A replay of the call will be available for 14 days, within a few
hours after the call ends. Investors may listen to the replay of
the call by dialing 888-203-1112 (U.S.) or +1-719-457-0820
(international), with the passcode 6788004. A replay of the webcast
will also be archived on Flamel's website for 90 days following the
call.
About Flamel Technologies. Flamel
Technologies SA's (NASDAQ: FLML) business model is to blend high
value internally developed products with its leading drug delivery
capabilities. The Company has a proprietary pipeline of niche
specialty pharmaceutical products, while its drug delivery
platforms are focused on the goal of developing safer, more
efficacious formulations of drugs to address unmet medical needs.
Its partnered pipeline includes biological and chemical drugs
formulated with its Medusa® and Micropump® (and its applications to
the development of liquid formulations, i.e. LiquiTime™ and of
abuse-deterrent formulations Trigger Lock™) proprietary drug
delivery platforms. Several Medusa-based products have been
successfully tested in clinical trials. The Company has developed
products and manufactures Micropump-based microparticles under
FDA-audited GMP guidelines. Flamel Technologies has collaborations
with a number of leading pharmaceutical and biotechnology
companies, including GlaxoSmithKline (Coreg CR®, carvedilol
phosphate). The Company is headquartered in Lyon, France and has
operations in St. Louis, Missouri, USA, and manufacturing
facilities in Pessac, France. Additional information may be found
at www.flamel.com.
This release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including certain plans, expectations, goals and projections
regarding financial results, product developments and technology
platforms. All statements that are not clearly historical in nature
are forward-looking, and the words "anticipate," "assume,"
"believe," "expect," "estimate," "plan," "will," "may," and similar
expressions are generally intended to identify forward-looking
statements. All forward-looking statements involve risks,
uncertainties and contingencies, many of which are beyond our
control that could cause actual results to differ materially from
those contemplated in such forward-looking statements. These risks
include risks that the acquisition of Éclat Pharmaceuticals may not
be successfully integrated or that certain payment acceleration
events may be triggered; the new hospital-based product under FDA
review may not be approved or such approval may be delayed; the
reacquisition of the exclusive rights to rights to develop and
commercialize IFN-β XL worldwide and identification of an
alternative strategic partner for the program may not be
successful; the identified opportunities will not result in
shorter-term, high value results; clinical trial results may not be
positive or our partners may decide not to move forward; management
transition may be disruptive or not succeed as planned; products in
the development stage may not achieve scientific objectives or
milestones or meet stringent regulatory requirements; products in
development may not achieve market acceptance; competitive products
and pricing may hinder our commercial opportunities; we may not be
successful in identifying and pursuing opportunities to develop our
own product portfolio using Flamel's technology; and the risks
associated with our reliance on outside parties and key strategic
alliances. These and other risks are described more fully in
Flamel's Annual Report on Form 20-F for the year ended December 31,
2011 that has been filed with the Securities and Exchange
Commission (SEC). All forward-looking statements included in this
release are based on information available at the time of the
release. We undertake no obligation to update or alter our
forward-looking statements as a result of new information, future
events or otherwise.
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024